Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors
出版年份 2023 全文链接
标题
Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 23, Issue 11, Pages 1117-1122
出版商
Informa UK Limited
发表日期
2023-10-05
DOI
10.1080/14737140.2023.2267754
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA RET fusion-positive NSCLC.
- (2022) Ravi Rajaram et al. JOURNAL OF CLINICAL ONCOLOGY
- A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).
- (2022) Nathan A. Pennell et al. JOURNAL OF CLINICAL ONCOLOGY
- Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
- (2022) Vivek Subbiah et al. NATURE MEDICINE
- 1656P Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): Update of the LIBRETTO-001 trial
- (2022) M. Kroiss et al. ANNALS OF ONCOLOGY
- Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
- (2022) Alexander Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
- (2022) Vivek Subbiah et al. LANCET ONCOLOGY
- An early look at selective RET inhibitor resistance: new challenges and opportunities
- (2021) Jessica J. Lin et al. BRITISH JOURNAL OF CANCER
- 20 years of precision medicine in oncology
- (2021) The Lancet LANCET
- Advances in Targeting RET-Dependent Cancers
- (2020) Vivek Subbiah et al. Cancer Discovery
- The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.
- (2020) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Selpercatinib: First Approval
- (2020) Anthony Markham DRUGS
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
- (2020) Lori J. Wirth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
- (2020) V. Subbiah et al. ANNALS OF ONCOLOGY
- Mechanisms of receptor tyrosine kinase activation in cancer
- (2018) Zhenfang Du et al. Molecular Cancer
- A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
- (2018) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started